InvestorsHub Logo
Followers 4
Posts 280
Boards Moderated 0
Alias Born 04/12/2012

Re: pcinsurto post# 11183

Thursday, 05/07/2020 1:43:36 PM

Thursday, May 07, 2020 1:43:36 PM

Post# of 14941
Cantor Fitzgerald analyst Brandon Folkes downgraded ANI Pharmaceuticals to Neutral from Overweight with a price target of $40, down from $78. The analyst sees uncertainty around the strategy that a new permanent CEO will bring. This, along with the recent FDA refuse to file letter of Cortrophin Gel, and the uncertainty that COVID-19 has placed on all company base businesses, warrants a cautious approach pending more visibility, Folkes tells investors in a research note.
-RG
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ANIP News